Leukemic N642H^vav/+ T/NKT cells expand upon transplantation. Splenic cells (Ly5.2⁺) from either aged control or diseased N642H^vav/+ mice were IV injected into NSG mice and analyzed. (A) Survival analysis (n ≥ 4 per genotype). (B) Quantification of GFP levels among transplanted Ly5.2⁺ cells in BM, spleen, and lung of NSG mice injected with control or N642H^vav/+ cells (n ≥ 3 per genotype; mean ± standard deviation). (C) Quantification of the leukemia type developed in the NSG recipients with N642H^vav/+ transplantation. (D) Relative quantification (percentages out of injected Ly5.2⁺ N642H^vav/+ cells) of N642H^vav/+ myeloid cells (CD11b⁺Gr1⁺), B cells (CD19⁺), T cells (CD3⁺NK1.1^–), NKT cells (CD3⁺NK1.1⁺), and NK cells (CD3^–NK1.1⁺) in BM, lung, and spleen of 4 to 5 of the diseased NSG mice with N642H^vav/+transplantation. (E) Representative FACS plots of TCRβ and TCRγδ gating starting from Ly5.2⁺ T cells (CD3⁺NK1.1^–) or NKT cells (CD3⁺NK1.1⁺) in BM of NSG mice with N642H^vav/+ transplantation. (F) Relative quantification of TCRβ or TCRγδ expression on transplanted Ly5.2⁺ N642H^vav/+ T cells (CD3⁺NK1.1^–) or NKT cells (CD3⁺NK1.1⁺) (n ≥ 4). (G) Relative quantification of CD4 or CD8 expression on transplanted Ly5.2⁺TCRβ⁺CD3⁺NK1.1^– or Ly5.2⁺ TCRβ⁺CD3⁺NK1.1⁺ N642H^vav/+ cells (n ≥ 4). Levels of significance were calculated using the Mantel-Cox test (A) or the Mann-Whitney test (B). ∗P < .05; ∗∗P < .01. FACS, fluorescence-activated cell sorting.